Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845298 · ClinicalTrials.gov registry record · NA
Immune Activation and Drug Absorption in HIV-Infected Patients
A NA study of HIV Infection, sponsored by Drexel University.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT01845298: Completed NA study of HIV Infection, sponsored by Drexel University.
NCT01845298 is a NA study of HIV Infection that has completed, run by Drexel University. The registered enrollment target is 7 participants, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01845298, a NA study of HIV Infection, has completed, sponsored by Drexel University.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' objective is to describe the variability of rifampicin absorption, markers of inflammation and gut damage, intestinal absorptive capacity, and intestinal permeability among HIV-infected volunteers. Rifampicin is the least well absorbed of the first-line anti-tuberculosis drugs. Rifampicin malabsorption is frequently observed in HIV-infected patients with active tuberculosis, but cannot be predicted by patient factors such as CD4+ T cell count, viral load, or the presence of diarrhea. The mechanisms for rifampicin malabsorption in HIV-infected patients are unknown. An understanding of mechanisms for rifampicin malabsorption could eventually lead to new therapeutic targets, with the ultimate goal of improving HIV/tuberculosis treatment outcomes.
Primary Outcome
The investigators will perform a pharmacokinetic study to assess rifampicin absorption among study subjects. Pharmacokinetic modeling will be used to assess the absorption rate constant (Ka) for each subject.
Conditions Studied
Interventions
- DRUG Rifampicin 600 mg
Study Locations (1)
Pennsylvania
- Drexel University College of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03-14 |
| Phase | NA |
What the finished NCT01845298 record still lists
NCT01845298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (97% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Rifampicin 600 mg is the first listed.
NCT01845298 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01845298 about?
NCT01845298 is a clinical study titled "Immune Activation and Drug Absorption in HIV-Infected Patients". The investigators' objective is to describe the variability of rifampicin absorption, markers of inflammation and gut damage, intestinal absorptive capacity, and intestinal permeability among HIV-infected volunteers. Rifampicin is the least well absorbed of the first-line anti-tuberculosis drugs. Ri...
What is the current status of trial NCT01845298?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2014-06. Estimated completion is 2016-03-14.
What conditions does trial NCT01845298 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT01845298?
The interventions under investigation include: Rifampicin 600 mg (DRUG).
Who is sponsoring clinical trial NCT01845298?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01845298 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01845298's enrollment target sits among peer trials
7 72nd of 73 higher than 2 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
RECRUITING · NA
-
The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
Technology-based Training Tool for PHAT Life
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia